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a  b s  t r a  c t
We  analyzed the 124 deaths reported in Portugal form flu  pandemic. The estimated mortality
rate was 1.17/100 000 population. 60% were males, the  average age was 47.6 and 66.1% had
at  least one risk factor. Chronic lung and heart diseases were the most common risk factors.
Viral pneumonia was the  major cause of death. 11% of the  deceased had no treatment
with  neuraminidase inhibitors and none was vaccinated against the pandemic strain of flu.
Compared to average life expectancy, we estimated that 3859 years of potential life were
lost.
In the future, we  should work on improved strategies for risk communication for health
professionals and general public.
© 2012 Escola Nacional de Saúde Pública. Published by Elsevier España, S.L. All rights
reserved.
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Anos potenciais de  vida perdidos
r  e  s u  m o
Em Portugal, durante a  pandemia de gripe A(H1N1) 2009 foram reportados 124 óbitos. A  taxa
de  mortalidade estimada foi de 1,17/100 000 habitantes. 60% dos falecidos eram do  sexo
masculino, a  média das idades foi de  47,6 anos e em 66,1% havia pelo menos um  factor de
risco. As doenças crónicas respiratórias e cardíacas foram os factores de  risco mais comuns.
A  pneumonia viral primária foi a  principal causa de  morte. 11% dos  falecidos não receberam
terapêutica com antivíricos e nenhum foi vacinado com a  vacina pandémica. Em relação à
esperança  média de vida, os anos potenciais de  vida perdidos foram 3859 anos.
No futuro em circunstâncias semelhantes, devemos melhorar as estratégias de
comunicação  do  risco para os profissionais de saúde e  população em geral.
©  2012 Escola Nacional de  Saúde Pública. Publicado por  Elsevier España, S.L. Todos os
direitos reservados.
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Um relatório preliminar deste estudo foi publicado na Revista
Portuguesa de Medicina Intensiva (Rev Port Med Int 2010;
17(4):11–19).
A preliminar report of this study has been published in  Revista
Portuguesa de Medicina Intensiva (Rev Port Med Int 2010;
17(4):11–19).
This report is dedicated to the families of victims of pandemic
influenza.
Introduction
Portugal activated their Contingency Plan1 for the flu pan-
demic on 24 April 2009 and it remained in force until 21 August
2009. The first case notified in  the country was  diagnosed on
29 April 2009.
As in other countries in  Portugal all deaths associated with
Flu A (H1N1) 2009 were reported. Throughout the pandemic
only related deaths were mandatory to be registered. From the
start of the Contingency Plan through to  the end of the  pan-
demic, which was officially declared over by the World Health
Organization (WHO) on 10 August 2010, there were 124 deaths.
The first occurred on 23  September 2009 and the last on 3
March 2010. The results of our analysis of reported deaths in
Portugal from the flu pandemic have a  great deal to contribute
to our understanding of the characteristics of infection from
the flu virus A (H1N1) 2009, and can help to improve standards
of preparation for future pandemics.
Objectives
To make a thorough examination of the deaths from the flu
pandemic according to  sex, age group, risk factors from severe
disease, hospital admission, length of hospital stay, causes of
death, antivirus treatment, vaccination status and the esti-
mated mortality rate and years of expected life lost.
Materials  and  methods
All deaths were confirmed by laboratory tests using RT-PCR.
We analyzed the data from the database of the Directorate-
General for Health (Direção-Geral da Saúde [DGS]) of the
Ministry of Health, which was subsequently validated by tele-
phone, email or by visits from representatives of DGS to the
hospitals.
The following were considered severe risk factors in  the
context of flu pandemic (H1N1) 20092:
1.  No risk factors
2. Pregnancy/postpartum (≤15 days after birth)
3.  Chronic lung disease (e.g. asthma, COPD, cystic fibrosis)
4. Chronic kidney disease
5.  Chronic heart disease (excluding isolated Arterial Hyper-
tension)
6. Chronic liver disease
7. Chronic hematologic disease (e.g. hemoglobinopathies,
excluding oncological disorders)
8. Neurological disease/chronic neuromuscular disease
9. Chronic metabolic disease (e.g. diabetes)
10. Cancer (e.g. solid and haematological tumours)
11. Immunosuppression (e.g. congenital, associated with HIV
and organ transplant, post-chemotherapy, immunother-
apy, steroids at immunosuppressant levels.)
12. Morbid obesity (<10 years old: IMC ≥25; ≥10 and <18 years
old: IMC ≥35; ≥18 years old: IMC ≥40)
13. Chronic therapy with salicylates in patients aged
<18 years
The following were considered as causes of death:
1. Viral infection, including primary viral pneumonia and
other causes of viral infection (e.g. encephalitis or myoperi-
carditis)
2. Secondary bacterial pneumonia (concurrent or as  a result
of viral infection and not contracted in hospital)
3. Decompensation due to  comorbidity
4. Complications or intercurrent disease during hospital-
ization (e.g. haemorrhage, stroke, pulmonary embolism,
barotraumas, nosocomial infections)
Figures from the Institute of National Statistics for the Por-
tuguese population on 31/12/20083 were used to calculate the
mortality rate. To calculate the expected years of life lost,
the age of each individual at the  time of death was subtracted
from the  average life expectancy at birth in Portugal for the
three-year period 2007–2009, specified by sex.4–7 The number
of years of potential life lost per 100 000 population was  calcu-
lated by dividing the total number of years lost by the estimate
of the Portuguese population younger than the  average life
expectancy.
To analyze the  data we  used PASW Statistics® version 18
and Microsoft Excel 2003. The comparison of the mean age was
calculated using the p value of Student’s t test and ANOVA. We
considered all non-significant differences in those where the
p-value was greater than 0.05.
Results
In Portugal 124 deaths caused by the flu pandemic were
reported. With the exception of one death which occurred at
home, all the patients (123: 99.2%) died in National Health
Service hospitals. The death toll represents a mortality rate
of 1.17 per 100 000 population. There were no deaths among
health professionals.
Age  and  sex
There were 74 male deaths (59.7%) and 50 female (40.3%). The
average age of death was 47.6 and the median age 49, there
was  no statistically significant difference (p = 0.873) between
the sexes, the average and median ages were 47.9 and 50 for
males and 47.3 and 47 for females, respectively. The youngest
who died was  5  months old and the oldest was  aged 88. Almost
half the deaths (46.8%) happened between the ages of 45 and
64  and around 1⁄3 (35.5%) were between the  ages of 15
and 44. Only 16 (12.9%) deaths occurred in the age group ≥65
(Table 1).
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Table 1 – Distribution of deaths from flu pandemic
(H1N1) 2009 according to age group, sex and mortality
rate per 100 000 population, from April 2009 to August
2010, Portugal.




00–04 years 2  (1.6) 0.38
05–14 years 4  (3.2) 0.37
15–64 years 102 (82.3) 1.43
15–44 years 44  (35.5) 1.00
45–64 years 58  (46.8) 2.13
≥65 years 16  (12.9) 0.85
Sex
Male 74  (59.7) 1.44
Female 50  (40.3) 0.91
Total 124 (100) 1.17
Source: DGS.
Table 2 – Number and percentage of deaths from flu
pandemic (H1N1) 2009, according to  risk factor,
from April 2009 to  August 2010, in Portugal.
Risk factors No.  (%)
Chronic lung disease  20  (24.4)
Chronic heart  disease 17  (20.7)
Immunosuppression 16  (19.5)
Chronic metabolic disease 15  (18.3)




Chronic liver disease 11  (13.4)
Morbid obesity 8  (9.8)
Chronic kidney disease 4  (4.9)
Pregnancy/post-partum 1  (1.2)
Source: DGS.
Risk  factors
Of the 124 deaths, 82 (66.1%) had at least one risk factor for seri-
ous disease. The average age for these patients was  48.5, which
was  higher than the 46.0 for those who had no risk factor
(n  = 42; 33.9%), but without statistical significance (p = 0.471).
Of the 82 patients with risk factors, 52 (63.4%) had only one
risk factor and 30  (36.6%) had more  than one risk factor. Of the
6 (7.3%) cases that had 3 or more  risk factors all of them were
over 45. Among the paediatric cases (aged <18), 6 (85.7%) of
the 7 who  died had, at least, 1 risk factor. The presence of risk
factors was 68.8% in the age group ≥65 and was lowest (56.8%)
among the age group 15–44.
Lung disease and chronic heart disease were the  most
common risk factors identified in respectively 20 (24.4%) and
17 (20.7%) patients, followed by immunosuppression in 16
(19.5%) cases (Table 2). Among the paediatric patients the most
common risk factor was neuromuscular disease, which was
present in  4 (66.7%) of the 6 children who  had risk factors.
Obesity classes I and II (IMC: ≥30 and <40) were not consid-
ered a risk factor. However, it  was mentioned in 18  cases, 12 of
Table 3 – Number and percentage (in descending order)
of deaths from flu pandemic (H1N1) 2009, according to
the cause of death; the total and the presence or absence
of risk factors, from April 2009 to August 2010, Portugal.




Viral infection 102 (82.2) 37  (88.1) 65 (79.2)
Primary viral
pneumonia

















4 (3.2) 0 (0) 4  (4.9)
Total 124 (100)  42  (100) 82 (100)
Source: DGS.
which had no risk factor. In the  group with chronic metabolic
diseases only one suffered from diabetes mellitus. Of the
14 cases with chronic neurological/neuromuscular disease,
three had Down’s syndrome.
Admission  to  hospital  and  to  ICU
Of 124 deaths, 123 (99.2%) occurred in National Health Service
hospitals. The other death happened at home. The average
length of internment for those who died was 15.0 days, the
median was 11, the maximum was 68 and the minimum 0
days. The average length of internment was 5.2 days for chil-
dren <18 years, 15.5 days for patients between 18  and 64 years
and 17.1 days for those ≥65. For patients with no risk factor
the average length of internment was 19.9 days and for those
with risk factors it was 13.0 days.
Of the 123 patients hospitalized, 95 (77.2%) were treated in
Intensive Care Units. 94 (98.9%) of these patients were treated
with invasive mechanical ventilation. Three of the patients
also had ECMO (Extra Corporeal Membrane Oxygenation)  out of a
total of 6 patients who have been treated with this procedure
in Portugal during flu pandemic.
Cause  of  death
Primary viral pneumonia diagnosed in  99 (79.8%) of the
124 patients, was  the most common cause of death, followed
by complications/intercurrent disease while in hospital and
decompensation caused by comorbidity, which occurred in 8.1
and 6.5% of cases respectively. Secondary bacterial pneumonia
was diagnosed in only 4 (3.2%) cases (Table 3).
The most common cause of death in the 7 children aged <18
was primary viral pneumonia in 6  cases (85.7%). In the other
case the cause of death was  decompensation from chronic
respiratory disease.
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Neuraminidase  inhibitor  therapy
In 6 cases out of the 124 deaths it is  not known if  they were
treated with neuraminidase inhibitors. We do know that it was
used with 105 patients (89.0%), but it  was not possible to estab-
lish the length of time between the onset of symptoms and
starting the therapy. They were all given oseltamivir, and 3
were also given zanamivir intravenously. 13  (11.0%) patients
had no antivirus therapy; 7 of these died in the  first 24 h after
admission and in 9 cases laboratory confirmation of disease
(RT-PCR) was  post-mortem.
Vaccination  status
82 (66.1%) of the patients had risk factors and therefore should
have been vaccinated. One of the patients contracted the  dis-
ease in the first week after being vaccinated and two, with
serious immunosuppression (hematologic malignancy) had
fallen ill in the interval between the 1st and 2nd vaccines.
None of the other 79  who had risk factors had been vacci-
nated. In 64 of these cases it was possible to work out how
long it would have been between the date they were admitted
to hospital and the completion of the vaccination scheme, if
they had been vaccinated according to guidelines for groups
at risk, according to the schedule of national vaccinations.
The length of time was as follows:
- for 29 (45.3%), more  than or equal to 4 weeks;
- for 5 (7.8%), more  than 3 weeks but less than 4;
-  for 30 (46.9%), less than 3 weeks.
Potential  years  of  life  lost
3859 was  the estimated figure for the number of potential
years of life lost, which is equivalent to 40.0 years per 100 000
population. The average number of potential years of life lost
for each person who  died was 31.
Discussion
In Portugal notification of death from flu pandemic was
mandatory. This study covers the 124 reported deaths which
were confirmed by laboratory tests RT-PCR. However, we must
accept that there might have been other deaths, where this
diagnosis was  not considered and so patients were not tested
or cases of false negative results due to technical problems in
sample collection or problems with the quality of laboratory
testing. Despite these possible limitations, which would have
also been true of other studies of the same kind, we are confi-
dent that the DGS database is reliable and if it does not cover
all, it does include the great majority of the deaths in Portugal.
It  is the first time in a  flu pandemic that only the death toll,
confirmed by laboratory tests, has been recorded, which may
help to explain discrepancies in  comparisons with the impact
of earlier pandemics. It should also be  noted that laboratory
testing for confirmation is not used to assess the mortality rate
during annual epidemics of seasonal flu.
These 124 deaths represent a mortality rate of 1.17/100 000
population, about a third of the estimate of the ECDC (up
to 3 per 100 000 population) in its “reasonable worst case
scenario”.8 This specific mortality rate, although higher than
the average for countries in the European Union,9 is within the
reference ranges for this region, and it is also higher than
the estimates for the  United States (USA) of 0.97/100 000.10
Without knowing the exact number of patients who were
affected and symptomatic we  cannot establish an  overall case
fatality rate or the case fatality rate for symptomatic illness.
In the USA11 and United Kingdom,12 the case fatality rate for
symptomatic illness has been estimated at 0.048% and 0.026%,
respectively.
The average age of patients who died was 47.6, with a  slight
predominance of males (59.7%); there was  no significant differ-
ence in  average ages of the sexes. The age group most affected
was  15–64, in particular the subgroup between 45 and 64 which
had a mortality rate of 2.13/100 000 population. The overrepre-
sentation of males was noted in  other European countries, for
example France13 (57%) and Holland14 (55%). The fact that it
affected younger age groups is also in  line with other studies,
the average age at death in the United Kingdom15 was  43 and
it was 52 in Holland.14
In Portugal, 87.1% of deaths happened in the under 65s,
which corroborated the global estimate that approximately
90% of those who died were under 65.16 This contrasts signifi-
cantly with figures for seasonal flu in this country, where more
than 80% of deaths occur in people who are 75 and over.17
25–50% of those who died were estimated to have no risk
factors for the flu pandemic.16 In Portugal 33.3% of deaths
occurred in  people with no risk factor; in United Kingdom
it was  23%.15 Although the values found in  our country are
within the reference ranges, the  variations found could have
been partially influenced by the  fact that the methodologies
used were not uniform and different weight was given to
some of the risk factors, for example, obesity. In this analy-
sis morbid obesity (BMI ≥ 40 in  adults and the corresponding
value for patients <18 years) was considered a  risk factor. If
non-morbid obesity is also included (IMC ≥ 30 in adults with a
corresponding value for children) means that there were only
23.6% patients without a risk factor.
The distribution of risk factors that were found in the Por-
tuguese population is very much the same as  the international
picture with the exception of pregnancy/post-partum. Only
one patient in Portugal died in these circumstances (0.8% of
total deaths), whereas the values described in the literature
in  other countries were between 6% and 9%.18,19 In our study
it was  not possible to come to any conclusions about this dif-
ference. Only one (14.3%) of the children did not have a  risk
factor and almost half (43.2%) of the deaths between 15 and
44 years did not present risk factors. In the  United Kingdom,
it was also among those between 25 and 44 years of age that
there was the highest percentage (32%) of deaths without risk
factors.15
Diffuse viral pneumonitis was the most common cause of
death (79.8%), which was independent of age group or the
existence of risk factors. This very high percentage of cases
of primary viral pneumonia, usually associated with ARDS
(Acute Respiratory Distress Syndrome), severe hypoxaemia, septic
shock and kidney failure, matches what is described in other
studies, for example in Australia18 and Canada19 and probably
explains why so many  of the patients were put on mechanical
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ventilation and had complications and intercurrent diseases
(8.1%). Throughout the  period of the  pandemic although there
was  often a  considerable delay before hospital admission there
were no reports of shortage of hospital beds in the ICUs.
Data from other studies indicate percentages of 26–38% for
deaths from bacterial pneumonia,18–21 whereas here accord-
ing to our data it was  only 3.2%; we  did not have enough
information to  explain this disparity, but it could be  related
to the effectiveness of the diagnosis by microbiological testing
and antibiotic treatment prior to  the collection of samples.
In 11.0% of deaths there had been no specific treatment
with neuraminidase inhibitors. In a similar study in South
Korea this percentage was  13%22 and 24% for patients who
died in hospital in the USA in September and October 2009.23
In our series, even though the majority died in the first  24  h
of hospitalization, the  delay in starting antiviral treatment in
the serious cases, because of, for example, waiting for confir-
mation of the  results of laboratory tests, can be  considered
a breach of the national technical guidelines issued by the
DGS.
In addition, for the first time in the history of pandemics,
there was  a vaccine available. In Portugal a  pandemic vaccine
with an adjuvant (Pandemrix)  was available from 26 October
2009 according to a schedule set down  according to risk fac-
tors. None of the  people who  died had been vaccinated for
pandemic flu, not even those whose risk factors should have
made them a priority. In a  study of 25  adults aged between 20
and 48 who were given a  vaccine similar to the one available
in Portugal, the  levels of seroconversion were 78%  and 88% at
14 and 21 days, respectively.24 In our study more  than 40% of
those with a risk factor and who died could have been vacci-
nated in time to prevent serious illness or death, but this did
not happen. On the contrary the national technical guidelines
were not respected and there was  a  lack of communication
and proper understanding of the risks involved on the part of
health professionals and the general public.
Using estimates as  a base for potential years of life lost
allows us to  have a  different perspective on the implications
of the pattern of death which we  do not get by just looking
at the numbers of deaths, in isolation.25 In this way we  can
see that in Portugal the number of potential years of life lost
was  3859 years, which corresponds to  40.0 years per 100 000
population, giving us a  clearer picture of the effect of the 124
registered deaths.
Conclusion
The mortality rates in Portugal were in general comparable to
those found in other developed countries. However in future
crises the Public Health Services should be prepared to impose
mandatory reporting for all the  most serious cases, for exam-
ple admission to a  hospital ward  or to an ICU, which would
be in line with best practice in  epidemiology, both clinical
and resource management. Equally there should be measures
in place to improve risk communication strategies for health
professionals and the  general public. An  analysis of potential
years of life lost, because it shows the impact of death in  real
terms rather than looking at the bald number of actual deaths,
gives more  insight into the effect of these deaths, and for this
reason should be  included wherever possible in the  evaluation
of the effect of illness that can be classed as pandemics.
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